U.S. markets open in 6 hours 3 minutes
  • S&P Futures

    +2.75 (+0.07%)
  • Dow Futures

    +10.00 (+0.03%)
  • Nasdaq Futures

    +38.00 (+0.27%)
  • Russell 2000 Futures

    -1.10 (-0.05%)
  • Crude Oil

    -0.34 (-0.48%)
  • Gold

    +11.20 (+0.63%)
  • Silver

    +0.41 (+1.60%)

    -0.0007 (-0.06%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.40 (-2.20%)

    -0.0056 (-0.40%)

    -0.1350 (-0.12%)

    -1,638.05 (-4.17%)
  • CMC Crypto 200

    -32.67 (-3.37%)
  • FTSE 100

    -4.64 (-0.06%)
  • Nikkei 225

    -54.25 (-0.19%)

Biotech Market is Rolling and These Companies Need to Be on Your Radar

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

HENDERSON, NV / ACCESSWIRE / October 2, 2018 / If you're an investor looking to make huge gains fast, Biotech and Cannabis stocks provide the best opportunity. Each market has a huge following of investors and traders alike, and the companies leading the sector are all working on high risk, high reward products that have the opportunity to send the company from growth play to major success story with one pivotal press release or event.

That’s why we always have our ear to the ground for the best opportunities in these sectors. Below are several plays that could make you a bundle in a flash. One in particular to pay attention to is Endonovo Therapeutics, Inc. (ENDV). This 5 cent stock has received price targets from research firms as high as 25 cents a share.

This company has been making progress for years. While the company is developing their non-invasive Immunotronics treatment for heart failure which has past pre-clinical and has had favorable results; the reason we're excited is about ENDV is they're under the radar SofPulse technology.

The non-invasive pain reduction treatment could render troublesome opioid prescriptions irrelevant. The company just released news that they have secured sales, marketing and distribution.

Now may be the time to act on ENDV before the revenues start rolling in.

Biotech and cannabis companies to look at include: Endonovo Therapeutics, Inc. (ENDV), Oragenics, Inc. (OGEN), Amarin Corporation plc (AMRN), Aurora Cannabis, Inc. (ACBFF) and Cronos Group, Inc. (CRON).

Endonovo Therapeutics, Inc. (ENDV)

Market Cap: $18.98M Share Price: $0.05

Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a distribution agreement with Magniant, LLC for the distribution of SofPulse®, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.

Alan Collier, Endonovo Chief Executive Officer, stated, "We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our Sofpulse device on a national level."

Oragenics, Inc. (NYSE American: OGEN)

Market Cap: $19.92 Share Price: $1.73

Oragenics, Inc. (OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced it will present and meet with investors at The MicroCap Conference on October 1, 2018, at 1:00 PM ET as part of Track 1 at The Essex House in New York City. The company will then present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018, at 1:00 PM ET as part of Track 6 in the Madeleine Room at the Sofitel Hotel in New York City.

Amarin Corporation plc (AMRN)

Market Cap: $5.19B Share Price: $17.56

Amarin reported remarkable data for its fish-oil pill Vascepa last week. A purified formulation of the omega 3 fatty acid EPA, Vascepa has been approved for reducing triglyceride levels in patients with triglyceride levels above 500 milligrams per deciliter (mg/dL) since 2012.

Aurora Cannabis, Inc. (OTCQX:ACBFF)

Market Cap: $9.35B Share Price: $9.77

ACBFF released fiscal fourth-quarter earnings and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange.

Aurora Chief Executive Terry Booth said, "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success."

The company's top line grew 223% to C$19.1 million, up from C$5.9 million in the year-earlier quarter.

Cronos Group, Inc. (CRON)

Market Cap: $2.05B Share Price: $11.60

Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across five continents. Cronos Group operates two wholly-owned Canadian licensed producers regulated under Health Canada's Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc., which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd., which is based in the Okanagan Valley, British Columbia. Cronos Group has multiple international production and distribution platforms across five continents.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and seventy-three thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of ENDV in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting. LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspecualtors.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/

SOURCE: ACR Communications LLC